Skip to main content
GENB logo

Generate Biomedicines, Inc. (GENB) Stock: Price, Forecast & Analyst Target

Generate Biomedicines, Inc. (GENB) — MoonshotScore 24/100 (Weak band), calculated Nov 18, 2026. Price $10.37 (-0.10%), as of the Nov 19, 2026 trading session; market cap $1.34B.

Educational signal · not a buy or sell recommendation · How to read this

$10.37 −$0.01 (-0.10%) Market Cap $1.34B

Generate Biomedicines, Inc. · GENB · NASDAQ

Generate Biomedicines, Inc. pioneers generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. The U.S.-based company focuses on developing protein-based drug modalities with a pipeline including candidates for severe asthma and CAR-T cell therapy.

Price as of Nov 19, 2026

Key Statistics

24 of 100

MoonshotScore v2 · Generate Biomedicines (GENB)

Weak
Business Quality Poor (16)
Financial Safety Okay (52)
Valuation Rich (32)
Growth Durability Flat (56)
Momentum Quiet (40)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality and an expensive valuation, though the balance sheet is only middling. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Rich; Growth Durability: Flat; Momentum: Quiet.

  • EPS beat 0 of the last 3 reports
  • Altman Z 2.68 · Piotroski F 2

Holding back: weak fundamentals, a rich price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for GENB (57 recorded, newest six shown)
RecordedScoreBand
32Weak
24Weak
25Weak
25Weak
24Weak
24Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$10.37
Change on the day-0.10%
52-week range$10.37 – $22.67
Market capitalisation$1.34B—
Shares traded on the day835.4K

Price & events

Other perspectives

Council score for Generate Biomedicines (GENB): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Neutral
Valuation Weak
Growth Durability Neutral
Momentum Neutral

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Moderate
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Strong
Debt/Equity Moderate
Gross Margin Negative

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Four of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens, Griffin-style lens, Simons-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Generate Biomedicines (GENB), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Generate Biomedicines, Inc. (GENB) is listed on NASDAQ. It employs 312 people and is led by Michael T. Nally. The market values it at $1.34B.

2 · Latest results

What do the latest results show for Generate Biomedicines (GENB)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 3 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$10M-$54M-$0.51 (diluted)
Dec 2025$3M-$55M—
Q1 FY2026$7M-$61M-$1.07 (diluted)
Q2 FY2026$6M-$67M-$0.52 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Generate Biomedicines (GENB)?

Short answer

What is holding it back is weak fundamentals, a rich price. The distress and quality screens read Altman Z 2.68 · Piotroski F 2. Trailing ratios: current ratio 5.01.

4 · What to check next?

What should you watch next at Generate Biomedicines (GENB)?

Short answer · as of

Current published price targets run low $30.00 · high $30.00 · consensus $30.00 · median $30.00 against a quoted price of $10.37 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Generate Biomedicines compare with its peers?

Short answer

Generate Biomedicines's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eton Pharmaceuticals, Inc. (ETON) Same industry, near in market value$61.99 Nov 18, 2026$1.79B98 5-pillar Nov 18, 2026
Nurix Therapeutics, Inc. (NRIX) Same industry, near in market value$14.10 Nov 18, 2026$1.54B97 5-pillar Nov 18, 2026
Aurinia Pharmaceuticals Inc. (AUPH) Same industry, near in market value$15.13 Nov 18, 2026$2.03B97 5-pillar Nov 18, 2026
Innoviva, Inc. (INVA) Same industry, near in market value$18.40 Nov 18, 2026$1.31B96 5-pillar Nov 18, 2026
Harmony Biosciences Holdings, Inc. (HRMY) Same industry, near in market value$33.11 Nov 18, 2026$1.94B96 5-pillar Nov 18, 2026
Veracyte, Inc. (VCYT) Same industry, near in market value$25.57 Nov 18, 2026$2.06B89 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
AnaptysBio, Inc. (ANAB) Same industry, near in market value$47.40 Nov 19, 2026$1.41B76 5-pillar Nov 18, 2026
LB Pharmaceuticals Inc (LBRX) Same industry, near in market value$40.04 Nov 19, 2026$1.30B69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.17 Nov 19, 2026$861M69 5-pillar Nov 18, 2026
Vor Biopharma, Inc. (VOR) Same industry, near in market value$18.52 Nov 19, 2026$1.14B66 5-pillar Nov 18, 2026
SpyGlass Pharma, Inc. Common Stock (SGP) Same industry, near in market value$30.78 Nov 19, 2026$1.03B64 5-pillar Nov 18, 2026
Generate Biomedicines (GENB) — this page$10.37$1.34B24

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$30.00 – $30.00
Consensus target
$30.00
Median target
$30.00

Consensus record · Captured .

Measured against a quoted price of $10.37 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
1
Identified insiders
1
Purchases
0
Sales
1
Other transactions
0

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held GENB in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20260.17%$29.51MAdded +52.9% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Generate Biomedicines (GENB)?

Read these with our analysis →

Common Questions About GENB

These answers are editorial: 1 of these 9 answers is drawn from the GENB research dossier (written Jun 13, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for GENB?

GENB carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Generate Biomedicines, Inc. pioneers generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics.

Is GENB a good stock to buy?

Stock Expert AI does not rate GENB buy, sell or hold. Generate Biomedicines, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the GENB stock price today?

The last price recorded for Generate Biomedicines, Inc. (GENB), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the GENB price target?

The analyst consensus price target for Generate Biomedicines, Inc. (GENB), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for GENB?

Generate Biomedicines, Inc. faces several significant risks inherent in early-stage biopharmaceutical development. A primary concern is the high probability of clinical trial failures, where investigational drugs may not demonstrate sufficient efficacy or safety, leading to project termination.

What are the key factors to evaluate for GENB?

Generate Biomedicines, Inc. (GENB) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Dividend Yield: None, consistent with a growth-oriented biopharmaceutical company reinvesting all capital into its pipeline and platform development. Not financial advice.

How frequently does GENB data refresh on this page?

GENB's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven GENB's recent stock price performance?

Generate Biomedicines, Inc. (GENB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Pioneering generative biology platform leveraging machine learning for novel protein discovery. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider GENB overvalued or undervalued right now?

Generate Biomedicines, Inc. (GENB) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.